Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

GSK256066

Phase 2Small molecule

GSK256066 is one of 118 small molecule programs targeting Rhinitis. It is currently in Phase 2.

5

Indications

10

Total Trials

0

Active Trials

117

Competitors

Pipeline

Status by Indication[3][1]

Indication

RhinitisActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Allergic RhinitisActive, not recruiting

AsthmaActive, not recruiting

Seasonal Allergic RhinitisActive, not recruiting

RhinitisPhase 2

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

Allergic RhinitisPhase 2

Active, not recruiting

AsthmaPhase 2

Active, not recruiting

Seasonal Allergic RhinitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK256066

Nucala

GGlaxo Dba Glaxosmithkline

Cinqair

Celexa

Atrovent

Boehringer Ingelheim

Arcoxia

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

DUPIXENT

Paracetamol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Trial2 trials

Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber

Completed· GSK logo

GSK·Phase 2·NCT00377728·44 enrolled

Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing

Completed· GSK logo

GSK·Phase 2·NCT00549744·78 enrolled

Asthma2 trials

This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge

Completed· GSK logo

GSK·Phase 2·NCT00445510·24 enrolled

Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma

Completed· GSK logo

GSK·Phase 2·NCT00380354·11 enrolled

Seasonal Allergic Rhinitis2 trials

A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)

Completed· GSK logo

GSK·Phase 2·NCT00612820·55 enrolled

A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis

Completed· GSK logo

GSK·Phase 2·NCT00612118·70 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients

Completed· GSK logo

GSK·Phase 2·NCT00549679·104 enrolled

Allergic Rhinitis1 trial

Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber

Completed· GSK logo

GSK·Phase 2·NCT00430157·45 enrolled

2 more indications

Rhinitis1 trial

A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis

Completed· GSK logo

GSK·Phase 2·NCT00464568·32 enrolled

Women1 trial

Endotoxin Challenge Study For Healthy Men and Women

Completed· GSK logo

GSK·Phase 1·NCT00515268·37 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for GSK256066. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GSK256066 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GSK256066. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GSK

Related News